Patients prescribed the antidepressant escitalopram see their symptoms improve and stay manageable more often than those taking Prozac, a major new medical analysis shows.
The study, published in The Lancet Psychiatry, evaluated nearly 10,000 people taking various medications for up to a year, bbc.co.uk reported. Researchers examined more than a dozen common antidepressants to determine which drugs best prevent patients from relapsing after initial recovery.
Escitalopram performed best at keeping patients free of depression symptoms over the study period, according to findings cited by bbc.co.uk. Two other medications, agomelatine and duloxetine, also performed well, while Prozac—known generically as fluoxetine—ranked just below them. Other widely used medicines, including sertraline, showed no better outcomes than Prozac in the comparative data.
Medical guidelines commonly recommend selective serotonin reuptake inhibitors, or SSRIs, as a primary treatment choice. These drugs increase serotonin levels in the brain, a neurotransmitter closely linked to mood regulation. Depression affects approximately one in six people in the UK, where treatment often involves a combination of medication and support.
Prof Eric Ruhé of Radboud University in The Netherlands noted that medication selection must remain tailored to the individual. “Nevertheless, our study can help inform the decisions that prescribers and patients make together: if you start an antidepressant, choose one that not only helps you to get well, but also keeps you well,” he said, according to bbc.co.uk.
Other specialists cautioned against making sweeping changes based on group averages. Dr Sameer Jauhar of Imperial College London stated that the research cannot predict which specific medication will work best for a particular patient. “I would not interpret these findings as a reason for someone who is responding well to their current antidepressant to change treatment,” he added.
Prof Allan Young from the Royal College of Psychiatrists emphasized that observed differences between the medicines were modest. Individual factors such as side effect profiles, previous treatment responses, and patient preferences still outweigh long-term statistical advantages when clinical decisions are made.
Escitalopram carries potential side effects, including sleep disturbances, constipation, and weight gain, though patients experience these reactions differently. When escitalopram or similar SSRIs prove ineffective or unsuitable, healthcare providers may recommend alternative classes, such as serotonin-norepinephrine reuptake inhibitors like duloxetine. Older tricyclic antidepressants, including amitriptyline, are prescribed less frequently today.
The mental health charity Mind reported that patients require clear information regarding both benefits and potential side effects before starting treatment. “It’s common for people to need to try more than one medication before they find the right treatment that works for them. And what works may change over time,” the charity stated, noting that talking therapies and mindfulness offer valuable supplementary support.
Medical guidelines advise patients to continue taking antidepressants for at least six months following clinical recovery to reduce the risk of relapse before tapering off gradually.
Escitalopram performed best at preventing relapse among nearly 10,000 studied patients, followed by agomelatine and duloxetine, with fluoxetine ranking just below them.
Specialists emphasize that the findings reflect population averages rather than individual outcomes, advising patients currently responding well to their medication not to switch treatments.
Worth a look